Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial

Table 1 Patient characteristics of the intention-to-treat population

Characteristic	Valganciclovir (n = 60)	Valacyclovir (n = 59)	P Value
Recipient
Age (yr)	48 ± 13	50 ± 11	0.224
Gender (male)	47 (78)	37 (63)	0.095
Previous transplantation	9 (15)	7 (12)	0.816
HLA mismatches (n)	3.5 ± 1.2	3.6 ± 1.5	0.508
CMV serostatus			0.289
D+/R-	7 (12)	4 (7)
D+/R+	44 (73)	49 (83)
D−/R+	9 (15)	6 (10)
Donor
Age (yr)	50 ± 16	49 ± 16	0.702
Donor type (deceased)	57 (95)	54 (92)	0.696
Expanded-criteria donor^a	34 (57)	32 (54)	0.935
Advanced chronic histologic damage^b	15 (25)	9 (15)	0.185
Primary immunosuppression^c
Cyclosporine + mycophenolate mofetil	25 (42)	35 (59)	0.081
Tacrolimus + mycophenolate mofetil	35 (58)	24 (41)
No induction therapy	25 (42)	34 (58)	0.119
Basiliximab	26 (43)	14 (24)	0.039
Thymoglobulin	9 (15)	11 (19)	0.775

Data are number of patients (percentage) or mean ± standard deviation. CMV, cytomegalovirus; D, donor; R, recipient
^aAccording to the United Network for Organ Sharing criteria
^bA minimum 1 of the following findings on donor procurement biopsy: moderate-to-severe vascular nephrosclerosis, diabetic nephropathy, and/or ≥ 15% of glomerulosclerosis. Procurement biopsy was performed in 61 selected donors considered to be at increased risk
^cLow-dose tacrolimus with basiliximab induction was used in recipients of grafts from highly marginal donors (age ≥ 70 years, donors with hypertension or diabetes with impaired renal function or biopsy findings of vascular nephrosclerosis, diabetic nephropathy and/or ≥ 15% of glomerulosclerosis, donors after cardiac death, and dual kidney transplantation)

ISSN: 1471-2334